LivaNova stock trades at EUR 66.75 ahead of November results

Published on 10/05/2026 at 15:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LivaNova raised 2026 revenue growth guidance to 8%-9% in the second quarter. LivaNova stock costs EUR 66.75 on October 5, 2026 after EUR 66.75.

LIVN, GB00BYMT0J19, Illustration mit AI erstellt.

LivaNova (ISIN GB00BYMT0J19) was trading at EUR 66.75 at Lang & Schwarz on October 5, 2026 at 3:14 p.m. CEST, unchanged from the EUR 66.75 prior close. According to BusinessWire on September 23, 2026, LivaNova will discuss its third-quarter 2026 results on November 4, 2026.

Revenue guidance moves higher

The scheduled results date gives investors a defined checkpoint for the raised outlook. In the second-quarter 2026 earnings call, LivaNova said full-year revenue growth should reach 8%-9%, up from the previous 7%-8% range.

According to Yahoo Finance on August 5, 2026, adjusted diluted earnings per share was USD 1.26 in the second quarter, up from USD 1.05 a year earlier. The same call put quarterly revenue at USD 391 million, up 9.8% on a constant-currency basis.

Second-quarter beat sets the base

MarketBeat reported on October 3, 2026, that quarterly earnings per share of USD 1.26 exceeded the USD 1.09 consensus by USD 0.17. Revenue of USD 390.59 million also exceeded the USD 380.50 million consensus, while revenue increased 10.8% from the second quarter of 2025.

The operating picture was mixed in one important respect. Yahoo Finance reported adjusted operating income of USD 91 million and an adjusted operating margin of 23% in the second quarter, compared with USD 77 million and 22% in the prior-year quarter, while adjusted free cash flow fell to USD 46 million from USD 48 million.

November results set the next test

For the next report, the key question is whether the higher growth outlook converts into cash generation as LivaNova funds capacity expansion and product development. The company said capital spending for 2026 would rise to USD 135 million from USD 120 million previously, while adjusted free cash flow guidance fell to USD 140 million-160 million from USD 160 million-180 million.

LivaNova's medical-device portfolio spans Cardiopulmonary and Neuromodulation, including oxygenators, heart-lung systems and vagus nerve stimulation therapies. Its NASDAQ quotation stood at USD 75.07 on October 2, 2026, against a 52-week range of USD 48.82-85.76, with a market capitalization of USD 4.1 billion.

EUR 66.75 at Lang & Schwarz

LivaNova was trading at EUR 66.75 at Lang & Schwarz on October 5, 2026 at 3:14 p.m. CEST, unchanged from the EUR 66.75 prior close on October 2, 2026. The reference price is an intraday euro quotation, not an official closing price.